CSTL
Castle Biosciences, Inc.
Price Chart
Latest Quote
$21.12
+0.87 (+4.30%)
Current Price
| Previous Close | $20.25 |
| Open | $20.39 |
| Day High | $21.15 |
| Day Low | $20.23 |
| Volume | 705,001 |
Stock Information
| Shares Outstanding | 30.33M |
| Total Debt | $36.72M |
| Cash Equivalents | $261.68M |
| Revenue | $339.92M |
| Net Income | $-12.83M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $640.57M |
| EPS (TTM) | $-0.42 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $415.61M |
| Sales | $339.92M |
| Income | $-12.83M |
| Book/sh | $15.23 |
| Cash/sh | $8.63 |
| Employees | 942 |
Financial Ratios
| Quick Ratio | 6.26 |
| Current Ratio | 6.75 |
| Debt/Eq | 7.96 |
Returns & Margins
| ROA | -3.96% |
| ROE | -2.85% |
| Gross Margin | 77.88% |
| Operating Margin | -22.00% |
| Profit Margin | -3.78% |
Ownership
| Insider Ownership | 2.73% |
| Institutional Ownership | 92.99% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -22.71 |
| P/S | 1.88 |
| P/B | 1.39 |
Analyst Data
| Recommendation | none |
| Target Price | $44.00 |
Technical Indicators
| SMA20 | $20.75 |
| SMA50 | $21.92 |
| SMA200 | $28.71 |
| RSI | 50.27 |
| ATR | 0.9216 |
| Shares Float | 26.77M |
| Short Float | 5.01% |
| Short Ratio | 2.86 |
| Volatility | 1.02 |
| Rel Volume | 2.11 |
Performance History
| Week | +0.52% |
| Month | +10.00% |
| Quarter | -17.82% |
| 6 Months | -45.92% |
| YTD | -45.20% |
| Year | +13.92% |
| 3 Years | +46.16% |
| 5 Years | -70.62% |
| 10 Years | -1.31% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $21.12 | 726,600 |
| 2026-06-17 | $20.25 | 310,400 |
| 2026-06-16 | $20.46 | 380,200 |
| 2026-06-15 | $20.66 | 220,500 |
| 2026-06-12 | $20.70 | 154,600 |
| 2026-06-11 | $21.01 | 215,200 |
| 2026-06-10 | $21.08 | 245,600 |
| 2026-06-09 | $21.08 | 289,500 |
| 2026-06-08 | $20.12 | 248,000 |
| 2026-06-05 | $21.01 | 212,500 |
| 2026-06-04 | $21.60 | 293,300 |
| 2026-06-03 | $20.39 | 516,600 |
| 2026-06-02 | $19.71 | 459,800 |
| 2026-06-01 | $20.97 | 312,100 |
| 2026-05-29 | $21.08 | 358,600 |
| 2026-05-28 | $22.11 | 299,800 |
| 2026-05-27 | $21.26 | 626,000 |
| 2026-05-26 | $19.69 | 401,900 |
| 2026-05-22 | $20.15 | 289,300 |
| 2026-05-21 | $20.54 | 327,300 |
| 2026-05-20 | $20.03 | 425,100 |
| 2026-05-19 | $19.20 | 343,500 |
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
đ° Latest News
How The Castle Biosciences (CSTL) Investment Story Is Evolving Without Fresh Analyst Commentary
Simply Wall St. âĸ 2026-06-09T11:07:52Z
How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets
Simply Wall St. âĸ 2026-05-24T16:13:44Z
Castle Biosciences, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-07T00:22:01Z
Castle Biosciences Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T00:07:45Z
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-06T22:30:11Z
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
Zacks âĸ 2026-05-06T16:06:00Z
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
Zacks âĸ 2026-05-06T16:01:00Z
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks âĸ 2026-05-06T15:57:00Z
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
Zacks âĸ 2026-05-06T15:50:00Z
JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
Zacks âĸ 2026-05-06T14:29:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $65,095,000 | $55,314,000 | $41,665,000 | $29,732,000 |
| Cost Of Revenue | $71,028,000 | $60,205,000 | $44,982,000 | $32,009,000 |
| Total Revenue | $344,229,000 | $332,069,000 | $219,788,000 | $137,039,000 |
| Operating Revenue | $344,229,000 | $332,069,000 | $219,788,000 | $137,039,000 |
| Expenses | ||||
| Interest Expense | $86,000 | $577,000 | $11,000 | $17,000 |
| Total Expenses | $387,039,000 | $323,399,000 | $287,765,000 | $228,181,000 |
| Other Income Expense | $1,610,000 | $555,000 | - | $18,287,000 |
| Other Non Operating Income Expenses | $144,000 | $555,000 | - | - |
| Net Non Operating Interest Income Expense | $11,686,000 | $12,339,000 | $10,612,000 | $3,951,000 |
| Interest Expense Non Operating | $86,000 | $577,000 | $11,000 | $17,000 |
| Operating Expense | $316,011,000 | $263,194,000 | $242,783,000 | $196,172,000 |
| Selling And Marketing Expense | $138,115,000 | $123,467,000 | $113,657,000 | $86,607,000 |
| General And Administrative Expense | $91,208,000 | $76,580,000 | $66,495,000 | $56,396,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-24,158,000 | $18,245,000 | $-57,466,000 | $-67,138,000 |
| Net Interest Income | $11,686,000 | $12,339,000 | $10,612,000 | $3,951,000 |
| Interest Income | $11,772,000 | $12,916,000 | $10,623,000 | $3,968,000 |
| Normalized Income | $-25,358,654 | $17,775,422 | $-57,466,000 | $-84,956,307 |
| Net Income From Continuing And Discontinued Operation | $-24,158,000 | $18,245,000 | $-57,466,000 | $-67,138,000 |
| Total Operating Income As Reported | $-42,810,000 | $8,670,000 | $-67,977,000 | $-72,855,000 |
| Net Income Common Stockholders | $-24,158,000 | $18,245,000 | $-57,466,000 | $-67,138,000 |
| Net Income | $-24,158,000 | $18,245,000 | $-57,466,000 | $-67,138,000 |
| Net Income Including Noncontrolling Interests | $-24,158,000 | $18,245,000 | $-57,466,000 | $-67,138,000 |
| Net Income Continuous Operations | $-24,158,000 | $18,245,000 | $-57,466,000 | $-67,138,000 |
| Pretax Income | $-29,514,000 | $21,564,000 | $-57,365,000 | $-68,904,000 |
| Interest Income Non Operating | $11,772,000 | $12,916,000 | $10,623,000 | $3,968,000 |
| Operating Income | $-42,810,000 | $8,670,000 | $-67,977,000 | $-91,142,000 |
| Depreciation Amortization Depletion Income Statement | $34,838,000 | $11,106,000 | $9,013,000 | $8,266,000 |
| Depreciation And Amortization In Income Statement | $34,838,000 | $11,106,000 | $9,013,000 | $8,266,000 |
| Amortization Of Intangibles Income Statement | $34,838,000 | $11,106,000 | $9,013,000 | $8,266,000 |
| Gross Profit | $273,201,000 | $271,864,000 | $174,806,000 | $105,030,000 |
| Special Income Charges | - | $0 | $0 | $18,287,000 |
| Per Share | ||||
| Diluted EPS | $-0.83 | $0.62 | $-2.14 | $-2.58 |
| Basic EPS | $-0.83 | $0.66 | $-2.14 | $-2.58 |
| Other | ||||
| Tax Effect Of Unusual Items | $265,346 | $85,422 | $0 | $468,693 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $9,877,000 | $37,583,000 | $-45,024,000 | $-76,631,000 |
| Total Unusual Items | $1,466,000 | $555,000 | $0 | $18,287,000 |
| Total Unusual Items Excluding Goodwill | $1,466,000 | $555,000 | $0 | $18,287,000 |
| Reconciled Depreciation | $40,771,000 | $15,997,000 | $12,330,000 | $10,543,000 |
| EBITDA (Bullshit earnings) | $11,343,000 | $38,138,000 | $-45,024,000 | $-58,344,000 |
| EBIT | $-29,428,000 | $22,141,000 | $-57,354,000 | $-68,887,000 |
| Diluted Average Shares | $28,986,000 | $29,255,000 | $26,802,000 | $26,054,000 |
| Basic Average Shares | $28,986,000 | $27,776,000 | $26,802,000 | $26,054,000 |
| Diluted NI Availto Com Stockholders | $-24,158,000 | $18,245,000 | $-57,466,000 | $-67,138,000 |
| Tax Provision | $-5,356,000 | $3,319,000 | $101,000 | $-1,766,000 |
| Gain On Sale Of Security | $1,466,000 | $555,000 | - | - |
| Amortization | $34,838,000 | $11,106,000 | $9,013,000 | $8,266,000 |
| Research And Development | $51,850,000 | $52,041,000 | $53,618,000 | $44,903,000 |
| Selling General And Administration | $229,323,000 | $200,047,000 | $180,152,000 | $143,003,000 |
| Other Gand A | $91,208,000 | $76,580,000 | $66,495,000 | $56,396,000 |
| Restructuring And Mergern Acquisition | - | $0 | $0 | $-18,287,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $371,299,000 | $349,606,000 | $273,934,000 | $272,802,000 |
| Total Assets | $578,556,000 | $531,235,000 | $453,340,000 | $447,329,000 |
| Total Non Current Assets | $217,459,000 | $171,081,000 | $157,705,000 | $155,041,000 |
| Other Non Current Assets | $3,769,000 | $1,228,000 | $1,440,000 | $1,110,000 |
| Non Current Accounts Receivable | $1,878,000 | $918,000 | $1,191,000 | $1,087,000 |
| Goodwill And Other Intangible Assets | $99,574,000 | $106,229,000 | $117,335,000 | $126,348,000 |
| Other Intangible Assets | $88,882,000 | $95,537,000 | $106,643,000 | $115,656,000 |
| Current Assets | $361,097,000 | $360,154,000 | $295,635,000 | $292,288,000 |
| Other Current Assets | $7,956,000 | $7,671,000 | $6,292,000 | $6,207,000 |
| Inventory | $10,254,000 | $8,135,000 | $7,942,000 | $3,980,000 |
| Receivables | $43,382,000 | $51,218,000 | $38,302,000 | $23,476,000 |
| Accounts Receivable | $43,382,000 | $51,218,000 | $38,302,000 | $23,476,000 |
| Cash Cash Equivalents And Short Term Investments | $299,505,000 | $293,130,000 | $243,099,000 | $258,625,000 |
| Cash And Cash Equivalents | $116,729,000 | $119,709,000 | $98,841,000 | $122,948,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $36,913,000 | $26,344,000 | $15,335,000 | $13,400,000 |
| Long Term Debt And Capital Lease Obligation | $35,171,000 | $24,401,000 | $14,198,000 | $11,623,000 |
| Long Term Debt | $9,640,000 | $9,745,000 | - | - |
| Current Debt And Capital Lease Obligation | $1,742,000 | $1,943,000 | $1,137,000 | $1,777,000 |
| Current Debt | $417,000 | $278,000 | - | - |
| Other Current Borrowings | $417,000 | $278,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $107,683,000 | $75,400,000 | $62,071,000 | $48,179,000 |
| Total Non Current Liabilities Net Minority Interest | $39,006,000 | $26,008,000 | $14,404,000 | $12,051,000 |
| Other Non Current Liabilities | $1,500,000 | - | - | - |
| Non Current Deferred Liabilities | $2,335,000 | $1,607,000 | $206,000 | $428,000 |
| Non Current Deferred Taxes Liabilities | $2,335,000 | $1,607,000 | $206,000 | $428,000 |
| Current Liabilities | $68,677,000 | $49,392,000 | $47,667,000 | $36,128,000 |
| Other Current Liabilities | $3,126,000 | $1,850,000 | $606,000 | $415,000 |
| Payables And Accrued Expenses | $24,598,000 | $11,819,000 | $16,083,000 | $8,678,000 |
| Payables | $18,711,000 | $6,901,000 | $10,669,000 | $4,731,000 |
| Accounts Payable | $18,711,000 | $6,901,000 | $10,268,000 | $4,731,000 |
| Total Tax Payable | - | $1,076,000 | $401,000 | $37,000 |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $470,873,000 | $455,835,000 | $391,269,000 | $399,150,000 |
| Total Equity Gross Minority Interest | $470,873,000 | $455,835,000 | $391,269,000 | $399,150,000 |
| Stockholders Equity | $470,873,000 | $455,835,000 | $391,269,000 | $399,150,000 |
| Gains Losses Not Affecting Retained Earnings | $267,000 | $230,000 | $136,000 | $-381,000 |
| Other Equity Adjustments | $267,000 | $230,000 | $136,000 | $-381,000 |
| Retained Earnings | $-224,284,000 | $-200,126,000 | $-218,371,000 | $-160,905,000 |
| Other | ||||
| Ordinary Shares Number | $29,686,314 | $28,483,195 | $27,410,532 | $26,553,681 |
| Share Issued | $29,686,314 | $28,483,195 | $27,410,532 | $26,553,681 |
| Tangible Book Value | $371,299,000 | $349,606,000 | $273,934,000 | $272,802,000 |
| Invested Capital | $480,930,000 | $465,858,000 | $391,269,000 | $399,150,000 |
| Working Capital | $292,420,000 | $310,762,000 | $247,968,000 | $256,160,000 |
| Capital Lease Obligations | $26,856,000 | $16,321,000 | $15,335,000 | $13,400,000 |
| Total Capitalization | $480,513,000 | $465,580,000 | $391,269,000 | $399,150,000 |
| Additional Paid In Capital | $694,860,000 | $655,703,000 | $609,477,000 | $560,409,000 |
| Capital Stock | $30,000 | $28,000 | $27,000 | $27,000 |
| Common Stock | $30,000 | $28,000 | $27,000 | $27,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $25,531,000 | $14,656,000 | $14,198,000 | $11,623,000 |
| Current Capital Lease Obligation | $1,325,000 | $1,665,000 | $1,137,000 | $1,777,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $39,211,000 | $33,780,000 | $29,841,000 | $25,258,000 |
| Current Accrued Expenses | $5,887,000 | $4,918,000 | $5,414,000 | $3,947,000 |
| Goodwill | $10,692,000 | $10,692,000 | $10,692,000 | $10,692,000 |
| Net PPE | $112,238,000 | $62,706,000 | $37,739,000 | $26,496,000 |
| Accumulated Depreciation | $-18,297,000 | $-12,833,000 | $-8,111,000 | $-7,848,000 |
| Gross PPE | $130,535,000 | $75,539,000 | $45,850,000 | $34,344,000 |
| Leases | $14,834,000 | $14,616,000 | $9,990,000 | $5,171,000 |
| Construction In Progress | $51,059,000 | $9,614,000 | $637,000 | $1,275,000 |
| Other Properties | $47,829,000 | $35,217,000 | $28,778,000 | $21,902,000 |
| Machinery Furniture Equipment | $9,568,000 | $8,847,000 | $6,445,000 | $5,996,000 |
| Land And Improvements | $7,245,000 | $7,245,000 | $0 | - |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $182,776,000 | $173,421,000 | $144,258,000 | $135,677,000 |
| Non Current Deferred Revenue | - | - | - | - |
| Current Deferred Revenue | - | - | - | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $28,326,000 | $36,540,000 | $-19,247,000 | $-47,287,000 |
| Operating Activities | ||||
| Operating Cash Flow | $64,347,000 | $64,866,000 | $-5,626,000 | $-41,655,000 |
| Cash Flow From Continuing Operating Activities | $64,347,000 | $64,866,000 | $-5,626,000 | $-41,655,000 |
| Operating Gains Losses | $-1,466,000 | $-555,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-36,021,000 | $-28,326,000 | $-13,621,000 | $-5,632,000 |
| Investing Cash Flow | $-60,367,000 | $-50,137,000 | $-16,183,000 | $-166,545,000 |
| Cash Flow From Continuing Investing Activities | $-60,367,000 | $-50,137,000 | $-16,183,000 | $-166,545,000 |
| Net Other Investing Changes | $-7,683,000 | - | - | $547,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-6,960,000 | $6,139,000 | $-2,298,000 | $1,515,000 |
| Cash Flow From Continuing Financing Activities | $-6,960,000 | $6,139,000 | $-2,298,000 | $1,515,000 |
| Net Other Financing Charges | $-11,657,000 | $-8,762,000 | $-5,134,000 | $-1,688,000 |
| Issuance Of Capital Stock | - | - | - | - |
| Net Common Stock Issuance | - | - | - | - |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-115,000 | $-97,000 | $-142,000 | $-122,000 |
| Issuance Of Debt | $190,000 | $10,000,000 | $0 | $0 |
| Interest Paid Supplemental Data | $59,000 | $434,000 | $11,000 | $16,000 |
| Income Tax Paid Supplemental Data | $1,601,000 | $2,503,000 | $198,000 | $120,000 |
| End Cash Position | $116,729,000 | $119,709,000 | $98,841,000 | $122,948,000 |
| Beginning Cash Position | $119,709,000 | $98,841,000 | $122,948,000 | $329,633,000 |
| Changes In Cash | $-2,980,000 | $20,868,000 | $-24,107,000 | $-206,685,000 |
| Proceeds From Stock Option Exercised | $4,622,000 | $4,998,000 | $2,978,000 | $3,325,000 |
| Net Issuance Payments Of Debt | $75,000 | $9,903,000 | $-142,000 | $-122,000 |
| Net Long Term Debt Issuance | $75,000 | $9,903,000 | $-142,000 | $-122,000 |
| Long Term Debt Payments | $-115,000 | $-97,000 | $-142,000 | $-122,000 |
| Long Term Debt Issuance | $190,000 | $10,000,000 | $0 | $0 |
| Net Investment Purchase And Sale | $2,019,000 | $-21,829,000 | $-2,575,000 | $-134,689,000 |
| Sale Of Investment | $190,733,000 | $183,900,000 | $186,500,000 | $0 |
| Purchase Of Investment | $-188,714,000 | $-205,729,000 | $-189,075,000 | $-134,689,000 |
| Net Business Purchase And Sale | $-18,727,000 | $0 | $0 | $-26,966,000 |
| Purchase Of Business | $-18,727,000 | $0 | $0 | $-26,966,000 |
| Net PPE Purchase And Sale | $-35,976,000 | $-28,308,000 | $-13,608,000 | $-5,437,000 |
| Sale Of PPE | $45,000 | $18,000 | $13,000 | $195,000 |
| Purchase Of PPE | $-36,021,000 | $-28,326,000 | $-13,621,000 | $-5,632,000 |
| Change In Working Capital | $13,601,000 | $-14,125,000 | $-6,630,000 | $-7,000 |
| Change In Other Current Liabilities | $-1,275,000 | $-1,289,000 | $852,000 | $-608,000 |
| Change In Other Current Assets | $1,006,000 | $1,584,000 | $-588,000 | $1,609,000 |
| Change In Payables And Accrued Expense | $9,680,000 | $-442,000 | $12,433,000 | $8,114,000 |
| Change In Accrued Expense | $6,602,000 | $3,930,000 | $6,726,000 | $7,532,000 |
| Change In Payable | $3,078,000 | $-4,372,000 | $5,707,000 | $582,000 |
| Change In Account Payable | $3,078,000 | $-4,372,000 | $5,707,000 | $582,000 |
| Change In Prepaid Assets | $-544,000 | $-1,142,000 | $-435,000 | $-1,224,000 |
| Change In Inventory | $-2,142,000 | $-193,000 | $-3,962,000 | $-1,680,000 |
| Change In Receivables | $6,876,000 | $-12,643,000 | $-14,930,000 | $-6,218,000 |
| Changes In Account Receivables | $6,876,000 | $-12,643,000 | $-14,930,000 | $-6,218,000 |
| Other Non Cash Items | $153,000 | $268,000 | $635,000 | $-18,129,000 |
| Stock Based Compensation | $45,893,000 | $50,320,000 | $51,219,000 | $36,321,000 |
| Amortization Of Securities | $-4,219,000 | $-6,685,000 | $-5,491,000 | $-1,368,000 |
| Deferred Tax | $-6,228,000 | $1,401,000 | $-223,000 | $-1,877,000 |
| Deferred Income Tax | $-6,228,000 | $1,401,000 | $-223,000 | $-1,877,000 |
| Depreciation Amortization Depletion | $40,771,000 | $15,997,000 | $12,330,000 | $10,543,000 |
| Depreciation And Amortization | $40,771,000 | $15,997,000 | $12,330,000 | $10,543,000 |
| Amortization Cash Flow | $34,838,000 | $11,106,000 | $9,013,000 | $8,266,000 |
| Amortization Of Intangibles | $34,838,000 | $11,106,000 | $9,013,000 | $8,266,000 |
| Depreciation | $5,933,000 | $4,891,000 | $3,317,000 | $2,278,000 |
| Gain Loss On Investment Securities | $-1,466,000 | $-555,000 | - | - |
| Net Income From Continuing Operations | $-24,158,000 | $18,245,000 | $-57,466,000 | $-67,138,000 |
| Change In Other Working Capital | - | - | $4,587,000 | $8,495,000 |
Fetched: 2026-06-20